The thing about Spruce Biosciences is that it has multiple catalysts, which are expected to come out of its congenital adrenal hyperplasia [CAH] program. A major issue with CAH is that it causes a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Everyday Health on MSN
The future of congenital adrenal hyperplasia (CAH) treatment: New and emerging therapies and technologies
In addition to new medications to treat this enzyme deficiency, research is underway on easier hormone sampling and fixing ...
Please provide your email address to receive an email when new articles are posted on . Children with congenital adrenal hyperplasia have a shorter median height and higher body weight at age 20 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results